Research finds cancer cells produce phenanthridinone, sparing normal cells from harm — Evidence Review

Researchers at RIKEN have developed a novel strategy that turns cancer cells’ own carbon monoxide into toxic anticancer compounds inside the tumor, potentially reducing side effects of chemotherapy. Most related studies broadly support the approach of tumor-selective drug activation, with several showing that exploiting unique tumor chemistry can lead to more targeted and effective cancer therapies (3, 12, 14).

• The new findings reinforce the growing trend of designing therapies that are only activated within the tumor microenvironment, minimizing harm to healthy tissue; similar in situ drug synthesis or release strategies have been investigated using other tumor-specific markers or conditions (12, 14, 15).
• Existing studies confirm that certain phenanthridinone derivatives (the drug product in the new study) are selectively toxic to cancer cells and have been explored as potential chemotherapeutic agents, providing a mechanistic rationale for their use (6, 7, 8, 9, 10).
• Research on targeted drug delivery systems and microenvironment-triggered therapies demonstrates that utilizing tumor-specific features (such as metabolic byproducts or enzymes) can enhance drug specificity and therapeutic outcomes, aligning with the RIKEN team's strategy (13, 15).

Study Overview and Key Findings

Targeting cancer cells without harming healthy tissue remains a major challenge in oncology. This study introduces an innovative method by which an inert precursor compound, delivered in a protective albumin shell, uses the carbon monoxide (CO) produced by cancer cells to catalyze the formation of a toxic anticancer agent directly inside those cells. This approach aims to limit systemic toxicity—one of the main drawbacks of traditional chemotherapy—and leverages natural differences between tumor and normal cell metabolism to achieve selectivity. The research is significant as it provides a proof-of-concept for a new class of tumor-activated therapies, using CO as a unique biochemical trigger only abundant in cancer environments.

Property	Value
Organization	RIKEN Pioneering Research Institute
Journal Name	Nature Communications
Authors	Katsunori Tanaka
Population	Human liver, cervical, breast, and lung cancer cells
Methods	In Vitro Study
Outcome	Drug production in cancer cells, safety in normal cells
Results	Phenanthridinone was produced in cancer cells but not in normal cells.

Literature Review: Related Studies

To assess how this study fits within the broader scientific landscape, we searched the Consensus database, which includes over 200 million research papers. The following search queries were used to identify relevant literature:

1. cancer cells drug production
2. phenanthridinone cancer selectivity
3. tumor-targeted drug synthesis mechanisms

Topic	Key Findings
How can drug production or activation be targeted to cancer cells?	- Tumor microenvironment-activated systems, including nanodrugs and enzyme- or metabolite-triggered approaches, can increase selectivity and reduce toxicity compared to conventional therapies (12, 14, 15). - Mechanism-based delivery systems, such as receptor-mediated uptake or microenvironment-responsive linkers, enable precise drug release at tumor sites (11, 13).
Are phenanthridinone and related compounds effective and selective?	- Phenanthridinone and its analogues show selective cytotoxicity against various cancer cell lines, with some derivatives more potent than existing agents and low toxicity toward normal cells (6, 7, 8, 9, 10). - Certain structural features of phenanthridinone influence its cancer selectivity and potency (6, 10).
What are the main strategies for overcoming drug resistance and toxicity in cancer therapy?	- Targeting metabolic differences (like glucose metabolism or ribosome biogenesis) and efflux mechanisms in cancer cells can improve drug accumulation and overcome resistance (2, 5). - In situ drug synthesis, either via synthetic cell-like particles or tumor-specific catalysts, is a promising direction for next-generation cancer therapeutics (3, 14).

---

How can drug production or activation be targeted to cancer cells?

Multiple studies have explored strategies that leverage unique features of the tumor microenvironment to activate or release drugs selectively within cancer cells. These include pH-responsive nanodrugs, enzyme-activated systems, and metabolite-triggered drug release—approaches that align closely with the RIKEN team's use of carbon monoxide as a tumor-specific trigger for in situ drug synthesis. Such methods aim to maximize anticancer effects while sparing healthy tissue.

• Tumor microenvironment-activated nanodrugs show improved uptake by cancer cells and increased drug release at tumor sites, reducing systemic toxicity (12, 14, 15).
• Drug delivery systems that utilize receptor-mediated endocytosis or microenvironment-responsive linkers have demonstrated enhanced selectivity and efficacy in preclinical studies (11, 13).
• The new RIKEN study’s use of CO as a trigger expands the toolbox of tumor-specific activation mechanisms, complementing established triggers like acidity, redox status, or enzyme levels (12, 13, 14).
• These approaches collectively represent a shift away from non-specific chemotherapy toward more personalized and precise cancer treatments (12, 13, 14, 15).

Are phenanthridinone and related compounds effective and selective?

Phenanthridinone derivatives, including those structurally similar to the compound produced in the RIKEN study, have been widely investigated for their anticancer properties. Several studies report that these molecules can selectively kill cancer cells, often with greater potency than existing drugs and limited effects on normal cells.

• Benzo[c]phenanthridine and phenanthridine derivatives demonstrate selective cytotoxicity in lung, breast, and liver cancer models, supporting their use as targeted therapeutics (6, 7, 8, 9, 10).
• Structural modifications, such as the presence of certain side chains or ring substitutions, can enhance the selectivity and activity of these compounds (6, 10).
• Some phenanthridinone derivatives function as topoisomerase inhibitors, induce apoptosis, and cause cell cycle arrest in cancer cells, mechanisms relevant to the observed effects in the RIKEN study (8, 9).
• The literature supports the RIKEN group’s choice of phenanthridinone as an anticancer agent produced within tumors, given its demonstrated selective toxicity (6, 7, 8, 9, 10).

What are the main strategies for overcoming drug resistance and toxicity in cancer therapy?

A recurring theme in the literature is the development of therapies that exploit metabolic or molecular differences between cancer and normal cells to overcome multidrug resistance (MDR) and reduce adverse effects. In situ drug synthesis—producing the active drug only within the tumor—emerges as a promising strategy for addressing both resistance and toxicity.

• Targeting altered metabolic pathways (such as glycolysis or ribosome biogenesis) can sensitize cancer cells to therapy and help overcome MDR (2, 5).
• Synthetic cell-like particles or nanomaterials capable of manufacturing anticancer proteins or compounds directly inside tumors have been shown to induce robust tumor cell death in vitro and in animal models (3, 14).
• The RIKEN study’s catalyst-in-albumin approach for site-specific generation of a cytotoxic agent fits within this broader context of tumor-specific prodrug activation (3, 14).
• These strategies reflect a growing interest in precision medicine for cancer, where drug action is confined to the tumor to enhance efficacy and minimize harm (2, 3, 5, 14).

Future Research Questions

While the RIKEN study demonstrates a promising proof-of-concept in cell culture, further research is essential to translate these findings toward clinical applications. Key areas for future investigation include the safety and pharmacokinetics of the approach in animal models, possible immune responses, and the potential to generalize this method to other tumor types or metabolic markers.

Research Question	Relevance
How safe and effective is in situ anticancer drug synthesis in animal models?	Animal studies are crucial to evaluate the pharmacokinetics, biodistribution, and toxicity profile of the system before clinical translation; prior work has mainly focused on in vitro results (3, 14).
Can tumor-specific carbon monoxide levels be used to predict and monitor therapy response?	Understanding the variability of CO production among tumor types and patients will be important for patient selection and therapy optimization (14).
What are the potential immune responses to albumin-encapsulated metal catalysts in vivo?	Immune reactions to the delivery vehicle could limit therapeutic efficacy or cause adverse effects; this has not yet been fully addressed in preclinical models (14, 15).
Can this strategy be adapted to other tumor-specific metabolites or markers?	Adapting the concept to different tumor signatures could broaden its applicability and potentially benefit a wider range of cancer patients (12, 13).
What is the long-term selectivity and resistance profile of phenanthridinone-based drugs synthesized in tumors?	Assessing whether tumors develop resistance to locally synthesized phenanthridinone derivatives, and whether selectivity is maintained over time, is essential for sustainable therapeutic outcomes (6, 7, 8, 9, 10).